Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19660210 | 0.81 | KMT2A (0.49) | KMT2AMEN1ALDH1A1MAPTNPC1 | |
| SCHEMBL16057598 | 0.78 | PTPN1 (0.63) | NPC1PTPN1 | |
| SCHEMBL5313340 | 0.77 | TSHR (0.72) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL19642604 | 0.77 | TSHR (0.46) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL928345 | 0.76 | PDPK1 (0.62) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL19642670 | 0.76 | ALDH1A1 (0.62) | TSHRKMT2AMEN1ALDH1A1MAPT | |
| SCHEMBL19642630 | 0.76 | GSK3B (0.61) | TSHRKMT2AALDH1A1MAPTLMNA | |
| SCHEMBL5066173 | 0.76 | GSK3B (0.63) | TSHRKMT2AMEN1NPC1 | |
| SCHEMBL19642328 | 0.76 | PDPK1 (0.65) | TSHRALDH1A1MAPTPDPK1PTPN1 | |
| SCHEMBL13831355 | 0.75 | RAB9A (0.39) | KMT2AMEN1ALDH1A1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| CN-116554152-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116531380-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20230121195-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2023-04-20 | — | — | US | disclosed |
| CN-110678459-B | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2023-04-04 | — | — | CN | disclosed |
| CN-109863140-B | 3-oxo-2, 6-diphenyl-2, 3-dihydropyridazine-4-carboxamide | 拜耳医药股份有限公司 | 2023-02-21 | — | — | CN | disclosed |
| EP-3464248-B1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma AG (DE) | 2021-09-08 | — | — | EP | disclosed |
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-06-22 | — | — | US | disclosed |
| EP-3580211-B1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AG (DE) | 2020-12-02 | — | — | EP | disclosed |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2020-07-30 | — | — | US | disclosed |
| CN-110678459-A | 2-heteroaryl-3-oxo-2, 3-dihydropyridazine-4-carboxamides for the treatment of cancer | 拜耳股份公司 | 2020-01-10 | — | — | CN | disclosed |
| EP-3464248-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | Bayer Pharma Aktiengesellschaft (DE) | 2019-04-10 | — | — | EP | disclosed |
| WO-2018146010-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2018-08-16 | — | — | WO | disclosed |
| WO-2017202816-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040035-B2 | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | AHR, HRH2, HRH4 | TSHR 2046/4885KMT2A 408/4885MEN1 4479/4885 |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | AHR, ARNT, HRH2 | TSHR 1509/4885KMT2A 300/4885MEN1 4404/4885 |
| US-20230121195-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | AHR, ARNT, HRH2 | TSHR 1509/4885KMT2A 300/4885MEN1 4404/4885 |
| US-20200237757-A1 | 3-OXO-2,6-DIPHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | AHR, HRH2, HRH4 | TSHR 2046/4885KMT2A 408/4885MEN1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.